Literature DB >> 2317817

Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice.

Y Tanaka1, H Eda, T Tanaka, T Udagawa, T Ishikawa, I Horii, H Ishitsuka, T Kataoka, T Taguchi.   

Abstract

The present study investigates a tumor model for cachectic mice. Among various murine transplantable tumors, used for assessing cytostatics, we identified colon 26 adenocarcinoma (colon 26) as capable of causing cachexia. Fifteen days after inoculation, the tumor grew to about 6% of the body weight causing substantial carcass weight loss of 3.4 g (14.5% of the carcass weight). When the tumor size was 2.7 g at 3 weeks after the inoculation, the carcass weight was 12 g less than the age-matched control. The tumor continued to grow while the mice maintained this weight, surviving for an average of 45 days. This extensive weight loss was essentially the wasting of adipose and muscle tissues. Hypoglycemia and hypercorticism occurred during the time of the weight loss. In addition, the colon 26 caused disorders of hepatic functions: the concentration of acute phase proteins in serum increased; the number of hepatic glucocorticoid-cytosol receptors decreased; and activities of hepatic catalase and drug-metabolizing enzymes decreased. On the other hand, noncachectic mice with Meth A fibrosarcoma gained weight, which was somewhat less than the control, and had neither hypoglycemia nor hypercorticism, although some mild disorders of hepatic functions were found. Mice bearing colon 26 is an appropriate model for elucidating the mechanism that causes cachexia.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2317817

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  74 in total

1.  Prostate cancer reduces endurance exercise capacity in association with reductions in cardiac and skeletal muscle mass in the rat.

Authors:  Peter J Esau; Elizabeth M Gittemeier; Alexander B Opoku-Acheampong; Korynne S Rollins; Dryden R Baumfalk; David C Poole; Timothy I Musch; Bradley J Behnke; Steven W Copp
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

2.  miR-142 regulates the tumorigenicity of human breast cancer stem cells through the canonical WNT signaling pathway.

Authors:  Taichi Isobe; Shigeo Hisamori; Daniel J Hogan; Maider Zabala; David G Hendrickson; Piero Dalerba; Shang Cai; Ferenc Scheeren; Angera H Kuo; Shaheen S Sikandar; Jessica S Lam; Dalong Qian; Frederick M Dirbas; George Somlo; Kaiqin Lao; Patrick O Brown; Michael F Clarke; Yohei Shimono
Journal:  Elife       Date:  2014-11-18       Impact factor: 8.140

3.  Taltirelin alleviates fatigue-like behavior in mouse models of cancer-related fatigue.

Authors:  John P Dougherty; Brian S Wolff; Mary J Cullen; Leorey N Saligan; Marvin C Gershengorn
Journal:  Pharmacol Res       Date:  2017-07-15       Impact factor: 7.658

4.  An AMP-activated protein kinase-stabilizing peptide ameliorates adipose tissue wasting in cancer cachexia in mice.

Authors:  Maria Rohm; Michaela Schäfer; Victor Laurent; Bilgen Ekim Üstünel; Katharina Niopek; Carolyn Algire; Oksana Hautzinger; Tjeerd P Sijmonsma; Annika Zota; Dasa Medrikova; Natalia S Pellegata; Mikael Ryden; Agné Kulyte; Ingrid Dahlman; Peter Arner; Natasa Petrovic; Barbara Cannon; Ez-Zoubir Amri; Bruce E Kemp; Gregory R Steinberg; Petra Janovska; Jan Kopecky; Christian Wolfrum; Matthias Blüher; Mauricio Berriel Diaz; Stephan Herzig
Journal:  Nat Med       Date:  2016-08-29       Impact factor: 53.440

5.  MG132-mediated inhibition of the ubiquitin-proteasome pathway ameliorates cancer cachexia.

Authors:  Liuping Zhang; Hua Tang; Yao Kou; Rui Li; Yueyong Zheng; Qiang Wang; Xiaoyu Zhou; Liangbin Jin
Journal:  J Cancer Res Clin Oncol       Date:  2013-03-28       Impact factor: 4.553

6.  Reversal of muscle atrophy by Zhimu and Huangbai herb pair via activation of IGF-1/Akt and autophagy signal in cancer cachexia.

Authors:  Pengwei Zhuang; Jinbao Zhang; Yan Wang; Mixia Zhang; Lili Song; Zhiqiang Lu; Lu Zhang; Fengqi Zhang; Jing Wang; Yanjun Zhang; Hongjun Wei; Hongyan Li
Journal:  Support Care Cancer       Date:  2015-08-18       Impact factor: 3.603

7.  Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse.

Authors:  Paola Aulino; Emanuele Berardi; Veronica M Cardillo; Emanuele Rizzuto; Barbara Perniconi; Carla Ramina; Fabrizio Padula; Enrico P Spugnini; Alfonso Baldi; Fabio Faiola; Sergio Adamo; Dario Coletti
Journal:  BMC Cancer       Date:  2010-07-08       Impact factor: 4.430

8.  Control of adipose tissue inflammation through TRB1.

Authors:  Anke Ostertag; Allan Jones; Adam J Rose; Maria Liebert; Stefan Kleinsorg; Anja Reimann; Alexandros Vegiopoulos; Mauricio Berriel Diaz; Daniela Strzoda; Masahiro Yamamoto; Takashi Satoh; Shizuo Akira; Stephan Herzig
Journal:  Diabetes       Date:  2010-06-03       Impact factor: 9.461

9.  Role of NF-kappaB and cytokine in experimental cancer cachexia.

Authors:  Wei Zhou; Zhi-Wei Jiang; Jie Tian; Jun Jiang; Ning Li; Jie-Shou Li
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

10.  Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo.

Authors:  G Strassmann; M Fong; C E Freter; S Windsor; F D'Alessandro; R P Nordan
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.